NURIX THERAPEUTICS, INC. Increase (Decrease) in Contract with Customer, Liability
NURIX THERAPEUTICS, INC. (NRIX) reported Increase (Decrease) in Contract with Customer, Liability of -$8.30 million for the 6-month period ending 2026-05-31, per its 10-Q filed 2026-07-09.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-07-09
- NURIX THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-05-31 was -$7.04M.
- NURIX THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-02-28 was -$1.25M.
- NURIX THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-11-30 was -$13.58M.
- NURIX THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-08-31 was -$7.89M.
- NURIX THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for fiscal 2025 was -$36.98M.
- NURIX THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for fiscal 2024 was -$28.55M, a 246.31% decline from fiscal 2023.
- NURIX THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for fiscal 2023 was $19.51M.
- NURIX THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for fiscal 2022 was -$26.63M, a 286.86% decline from fiscal 2021.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 3 month as first filed | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 6 month as first filed | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 9 month as first filed | Increase (Decrease) in Contract with Customer, Liability 12 month | Increase (Decrease) in Contract with Customer, Liability 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-05-31 | -$7.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-09 | -$8.30M 10-Q · filed 2026-07-09 | -$21.87M derived: sum of 3 quarters · filed 2026-07-09 | -$29.77M derived: sum of 4 quarters · filed 2026-07-09 | ||||
| 2026-02-28 | -$1.25M 10-Q · filed 2026-04-08 | -$14.83M derived: sum of 2 quarters · filed 2026-04-08 | -$22.72M derived: sum of 3 quarters · filed 2026-04-08 | -$28.41M derived: sum of 4 quarters · filed 2026-07-09 | ||||
| 2025-11-30 | -$13.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | -$21.47M derived: sum of 2 quarters · filed 2026-01-28 | -$27.15M derived: sum of 3 quarters · filed 2026-07-09 | -$36.98M 10-K · filed 2026-01-28 | ||||
| 2025-08-31 | -$7.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-09 | -$13.58M derived: sum of 2 quarters · filed 2026-07-09 | -$23.40M 10-Q · filed 2025-10-09 | -$36.69M derived: sum of 4 quarters · filed 2026-07-09 | ||||
| 2025-05-31 | -$5.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-09 | -$15.51M 10-Q · filed 2026-07-09 | -$28.79M derived: sum of 3 quarters · filed 2026-07-09 | -$36.38M derived: sum of 4 quarters · filed 2026-07-09 | ||||
| 2025-02-28 | -$9.83M 10-Q · filed 2026-04-08 | -$23.11M derived: sum of 2 quarters · filed 2026-04-08 | -$30.70M derived: sum of 3 quarters · filed 2026-04-08 | -$25.79M derived: sum of 4 quarters · filed 2026-04-08 | ||||
| 2024-11-30 | -$13.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | -$20.87M derived: sum of 2 quarters · filed 2026-01-28 | -$15.96M derived: sum of 3 quarters · filed 2026-01-28 | -$28.55M 10-K · filed 2026-01-28 | ||||
| 2024-08-31 | -$7.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-09 | -$2.68M derived: sum of 2 quarters · filed 2025-10-09 | -$15.27M 10-Q · filed 2025-10-09 | $35.58M derived: sum of 4 quarters · filed 2026-01-28 | ||||
| 2024-05-31 | $4.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-09 | -$7.68M 10-Q · filed 2025-07-09 | $43.16M derived: sum of 3 quarters · filed 2026-01-28 | $26.70M derived: sum of 4 quarters · filed 2026-01-28 | ||||
| 2024-02-29 | -$12.59M 10-Q · filed 2025-04-08 | $38.25M derived: sum of 2 quarters · filed 2026-01-28 | $21.79M derived: sum of 3 quarters · filed 2026-01-28 | $16.11M derived: sum of 4 quarters · filed 2026-01-28 | ||||
| 2023-11-30 | $50.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $34.37M derived: sum of 2 quarters · filed 2026-01-28 | $28.70M derived: sum of 3 quarters · filed 2026-01-28 | $19.51M 10-K · filed 2026-01-28 | ||||
| 2023-08-31 | -$16.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-11 | -$22.14M derived: sum of 2 quarters · filed 2024-10-11 | -$31.33M 10-Q · filed 2024-10-11 | -$35.61M derived: sum of 4 quarters · filed 2025-01-28 | ||||
| 2023-05-31 | -$5.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-11 | -$14.86M 10-Q · filed 2024-07-11 | -$19.14M derived: sum of 3 quarters · filed 2025-01-28 | -$28.44M derived: sum of 4 quarters · filed 2025-01-28 | ||||
| 2023-02-28 | -$9.18M 10-Q · filed 2024-04-10 | -$13.47M derived: sum of 2 quarters · filed 2025-01-28 | -$22.76M derived: sum of 3 quarters · filed 2025-01-28 | -$32.19M derived: sum of 4 quarters · filed 2025-01-28 | ||||
| 2022-11-30 | -$4.28M derived: 10-K 12 month − 10-Q 9 month · filed 2025-01-28 | -$13.57M derived: sum of 2 quarters · filed 2025-01-28 | -$23.01M derived: sum of 3 quarters · filed 2025-01-28 | -$26.63M 10-K · filed 2025-01-28 | ||||
| 2022-08-31 | -$9.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-12 | -$18.72M derived: sum of 2 quarters · filed 2023-10-12 | -$22.34M 10-Q · filed 2023-10-12 | -$18.74M derived: sum of 4 quarters · filed 2023-10-12 | ||||
| 2022-05-31 | -$9.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-13 | -$13.05M 10-Q · filed 2023-07-13 | -$9.45M derived: sum of 3 quarters · filed 2023-07-13 | -$18.70M derived: sum of 4 quarters · filed 2023-07-13 | ||||
| 2022-02-28 | -$3.62M 10-Q · filed 2023-04-13 | -$1.62M 10-Q · filed 2022-04-08 | -$17.00K derived: sum of 2 quarters · filed 2023-04-13 | -$9.27M derived: sum of 3 quarters · filed 2023-04-13 | -$6.36M derived: sum of 4 quarters · filed 2023-04-13 | |||
| 2021-11-30 | $3.60M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | -$5.65M derived: sum of 2 quarters · filed 2023-02-09 | -$2.74M derived: sum of 3 quarters · filed 2023-02-09 | $14.25M 10-K · filed 2023-02-09 | $6.75M 10-K · filed 2022-01-28 | |||
| 2021-08-31 | -$9.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-06 | -$6.34M derived: sum of 2 quarters · filed 2022-10-06 | $10.65M 10-Q · filed 2022-10-06 | $8.15M 10-Q · filed 2021-10-14 | $11.46M derived: sum of 4 quarters · filed 2022-10-06 | |||
| 2021-05-31 | $2.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-07 | $19.90M 10-Q · filed 2022-07-07 | $12.40M 10-Q · filed 2021-07-13 | $20.71M derived: sum of 3 quarters · filed 2022-07-07 | $16.62M derived: sum of 4 quarters · filed 2022-07-07 | |||
| 2021-02-28 | $16.99M 10-Q · filed 2022-04-08 | $17.80M derived: sum of 2 quarters · filed 2022-04-08 | $13.71M derived: sum of 3 quarters · filed 2022-04-08 | $10.53M derived: sum of 4 quarters · filed 2022-04-08 | ||||
| 2020-11-30 | $811.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-01-28 | -$3.27M derived: sum of 2 quarters · filed 2022-01-28 | -$6.46M derived: sum of 3 quarters · filed 2022-01-28 | $48.18M 10-K · filed 2022-01-28 | ||||
| 2020-08-31 | -$4.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-14 | -$7.27M derived: sum of 2 quarters · filed 2021-10-14 | $47.37M 10-Q · filed 2021-10-14 | $45.51M derived: sum of 4 quarters · filed 2022-01-28 | ||||
| 2020-05-31 | -$3.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-13 | $51.45M 10-Q · filed 2021-07-13 | $49.59M derived: sum of 3 quarters · filed 2022-01-28 | |||||
| 2020-02-29 | $54.63M 10-Q · filed 2021-04-13 | $52.77M derived: sum of 2 quarters · filed 2022-01-28 | ||||||
| 2019-11-30 | -$1.86M derived: 10-K 12 month − 10-Q 9 month · filed 2022-01-28 | $16.89M 10-K · filed 2022-01-28 | ||||||
| 2019-08-31 | $18.75M 10-Q · filed 2020-10-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |